Dual roles of ARID1A in both mucin production and secretion suggest susceptibilities of gastric signet ring cell carcinoma

Chong Chen, Hongyu Liu, Ailing Zhong, Zhenghao Lu, Jiaxin Li, Mengsha Zhang, Y F Wang, Limin Gao, Xiangyu Pan, Xuelan Chen, Jingyao Chen, Lanxin Zhang, Siyu He, Xinyuan Wang, Xudong Wan, Xintong Deng, Tingfa Peng, Jian Song, Jiajia Du, Kun Yang, Kai Liu, Xin‐Zu Chen, Xiaolong Chen, Zhe Feng, Baohong Wu, Lin-Yong Zhao, Weihan Zhang, Shengyong Yang, Lu Chen, Cheng-Jian Zhao, Zhihong Xue, Lunzhi Dai, Feifei Na, Jian-Kun Hu, Yu LiuResearch Square 2024 · DOI

TL;DR

Researchers have identified ARID1A as a critical tumor suppressor in gastric signet ring cell carcinoma (SRCC), a particularly lethal form of stomach cancer. The study reveals that ARID1A loss acts as a "double whammy": it simultaneously cranks up mucin production via the non-canonical SWI/SNF complex (specifically involving BRD9) and blocks mucin secretion by downregulating the protein Scinderin (SCIN).

What Problem Does This Paper Address?

Signet ring cell carcinoma (SRCC) is a highly aggressive cancer characterized by cells with a massive, mucin-filled vacuole that pushes the nucleus to the periphery, making the cell look like a "signet ring." While its incidence is rising, we have lacked effective animal models and a clear understanding of the molecular "drivers" that create this unique and deadly morphology.

The authors set out to determine if mutations in ARID1A—a gene frequently altered in gastric cancers—are responsible for the SRCC phenotype and whether these pathways offer any "druggable" vulnerabilities.

Methods

The team employed a sophisticated "multi-omics" approach combined with a novel modeling strategy:

  • Organoid-Initiated Precision Cancer Models (OPCMs): Instead of slow, traditional transgenic mice, they used CRISPR/Cas9 to edit genes (Trp53, Pten, and Arid1a) in mouse gastric organoids, which were then transplanted back into mice (both subcutaneously and orthotopically into the stomach wall).
  • Multi-Omics Profiling: They used RNA-seq to look at gene expression, ATAC-seq to measure chromatin accessibility (how "open" the DNA is), and CUT&Tag to map exactly where specific proteins (like ARID1A and BRD9) bind to the genome.
  • Pharmacological Inhibition: They tested dBRD9 (a chemical degrader of the BRD9 protein) to see if they could reverse the cancer's progression.

Datasets

The study utilized several key resources:

  • Human Clinical Data: Genetic analysis of 171 diffuse-type gastric carcinoma samples from the cBioPortal (TCGA-STAD cohort).
  • Validation Cohorts: The Korea University cohort (GSE26899) and the Cancer Cell Line Encyclopedia (CCLE).
  • New Data: The authors generated and deposited their own extensive RNA-seq, ATAC-seq, and CUT&Tag datasets into the NCBI GEO (GSE232292).

Key Insights and Ideas

  • The Mucin Trap: The defining "signet ring" look isn't just about making too much mucin; it's about the cell's inability to get rid of it. ARID1A normally promotes the expression of Scin (Scinderin), which is essential for exocytosis (secreting stuff out of the cell). Without ARID1A, Scin levels drop, and mucin gets trapped inside, bloating the cell.
  • Epigenetic Reprogramming: ARID1A is part of the SWI/SNF chromatin remodeling complex. When it’s gone, the complex "remodels" itself. A non-canonical version of this complex, featuring the protein BRD9, takes over and opens up the DNA near mucin genes (like Muc1 and Muc20), forcing the cell to overproduce them.
  • A Druggable Vulnerability: Because the overproduction of mucin depends on BRD9, the researchers found that SRCC cells are uniquely sensitive to BRD9 inhibition. This provides a potential therapeutic "hook" for a cancer that currently lacks targeted treatments.

Key Results

  • Validation of ARID1A: While Trp53 and Pten loss caused general hyperplasia, only the addition of Arid1a loss (the "TPA" model) successfully recapitulated the classic SRCC histology in mice.
  • Survival Impact: Mice with TPA tumors had significantly shorter survival rates (median 67–142 days) compared to control groups, which often failed to form tumors at all.
  • Therapeutic Reversal: Treating TPA organoids and mice with the BRD9 inhibitor dBRD9 significantly reduced tumor growth, decreased the proportion of signet ring cells, and restored a more "normal" cellular appearance.
  • Genomic Frequency: The study confirmed that ARID1A alterations occur in roughly 39% of human diffuse-type gastric cancers, often co-occurring with TP53 and PTEN mutations.

Limitations and Future Work

The authors acknowledge that ARID1A's role is highly context-dependent; in some other cancers (like liver cancer), it can actually act as an oncogene depending on the stage of the disease. Furthermore, while BRD9 inhibition looks promising in a lab setting, the systemic effects—particularly on tumor-infiltrating immune cells—need to be carefully evaluated before moving toward human trials. Future work will likely focus on testing these BRD9 inhibitors in combination with existing therapies like immune checkpoint blockers.

Summary updated

Abstract

<title>Abstract</title> Signet ring cell carcinoma (SRCC) is a lethal malignancy with unique histologic features, characterized with large vacuoles and compressed nuclei. Gastric SRCC is the most common SRCC, and its incidence is increasing recently. However, the driver genes of SRCC and the molecular mechanisms underlying its unusual histology remain unclear. Here, we developed a new type of gastric SRCC mouse models with gene-edited premalignant gastric organoids and validated <italic>ARID1A</italic>, one of the most frequently mutated genes in SRCC, as a <italic>bona fide</italic> tumor suppressor gene of gastric SRCC. Mechanistically, through CUT/Tag and ATAC-seq analyses, we found that <italic>Arid1a</italic> directly regulated the expressions of secretory factors <italic>Scin</italic> and on the other hand, <italic>Arid1a</italic> loss reprogrammed the genome binding of the SWI/SNF complexes and increased the expressions of mucin genes through the binding of <italic>Brd9</italic>, a component of the noncanonical SWI/SNF complex. Inhibiting <italic>Brd9</italic> reversed the pathology of <italic>Arid1a</italic> mutant SRCC. Thus, our studies revealed dual roles of <italic>ARID1A</italic> in restraining SRCC through both mucin production and secretion. These findings offer new insights into the susceptibilities of <italic>ARID1A</italic> deficient SRCC.
BibTeX
@inproceedings{chen2024dual,
  author = {Chong Chen and Hongyu Liu and Ailing Zhong and Zhenghao Lu and Jiaxin Li and Mengsha Zhang and Y F Wang and Limin Gao and Xiangyu Pan and Xuelan Chen and Jingyao Chen and Lanxin Zhang and Siyu He and Xinyuan Wang and Xudong Wan and Xintong Deng and Tingfa Peng and Jian Song and Jiajia Du and Kun Yang and Kai Liu and Xin‐Zu Chen and Xiaolong Chen and Zhe Feng and Baohong Wu and Lin-Yong Zhao and Weihan Zhang and Shengyong Yang and Yuan Wang and Lu Chen and Cheng-Jian Zhao and Zhihong Xue and Lunzhi Dai and Feifei Na and Jian-Kun Hu and Yu Liu},
  title = {{Dual roles of ARID1A in both mucin production and secretion suggest susceptibilities of gastric signet ring cell carcinoma}},
  booktitle = {Research Square},
  year = {2024},
  doi = {10.21203/rs.3.rs-5298469/v1},
}
Figure